5-FU-based Chemotherapy in Pancreatic Neuroendocrine Neoplasms: Predictive and Prognostic Markers for Treatment und Survival

#852

Introduction: Chemotherapy with 5-FU and Streptozotocin (STZ) represents a standard of care for patients with metastatic pancreatic neuroendocrine neoplasms (PNENs). However, data to identify predictive and prognostic markers are limited.

Aim(s): Evaluation of clinicopathological characteristics and possible predictive and prognostic markers of patients with PNENs.

Materials and methods: We retrospectively analyzed 41 patients with PNEN who were treated at the University Hospital Marburg between 2000 and 2013. Dihydropyrimidin-Dehydrogenase (DPD) and Thymidylat-Synthase (TS) expression was correlated with treatment response in 19 patients who had available tumor tissue and response data. The median overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier and Cox regression methods, respectively.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Krug S, Boch M, Rinke A, Nimphius W, Müller D,

Keywords: 5-fluorouracil, DPD, PNEN,